Population-based open-label clinical effectiveness assessment of the cysteinyl leukotriene receptor antagonist pranlukast
Although the efficacy of cysteinyl leukotriene receptor antagonists in asthma therapy has been established through controlled clinical trials, there are no data concerning the effectiveness of their use in clinical practice, in which there is no rigid selection based on specific inclusion and exclus...
Main Authors: | Gen Tamura, Hiroshi Inoue, Junichi Chihara, Tamotsu Takishima |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2000-01-01
|
Series: | Allergology International |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1323893015314052 |
Similar Items
-
Population pharmacokinetics of pranlukast hydrate dry syrup in children with bronchial asthma
by: Ryosuke Inoue, et al.
Published: (2003-01-01) -
A Double-Blind Non-inferiority Clinical Study of Montelukast, a Cysteinyl Leukotriene Receptor 1 Antagonist, Compared with Pranlukast in Patients with Seasonal Allergic Rhinitis
by: Kimihiro Okubo, et al.
Published: (2008-01-01) -
Improved Case of Bronchial Asthma by Re-administration of Pranlukast from Montelukast: Evaluation of Eosinophilic Inflammation in the Peripheral Airway
by: Hiroyuki Ohbayashi
Published: (2005-01-01) -
Effects of Pranlukast Hydrate on Airway Hyperresponsiveness in Non-Asthmatic Patients with Japanese Cedar Pollinosis
by: Hironori Sagara, et al.
Published: (2009-01-01) -
Pranlukast Antagonizes CD49f and Reduces Stemness in Triple-Negative Breast Cancer Cells
by: Velázquez-Quesada I, et al.
Published: (2020-05-01)